Primary Tumor Resection Provides No OS Benefit in Asymptomatic Colorectal Cancer With Unresectable Metastases
The data suggest that primary tumor resection does not improve overall survival, but chemotherapy does.
American Society of Clinical Oncology (ASCO)
Factors Related to Adherence to Oral Multiple Myeloma Therapy
Researchers identified socioeconomic and demographic factors related to oral treatment adherence in patients with multiple myeloma.
GOC Program Improved Outcomes for Cancer Patients During COVID-19 Pandemic
The program was associated with significant reductions in patients’ length of stay in the ICU, ICU mortality, and in-hospital mortality.
Medicaid Expansion May Have Improved Access to Cancer Trials
The expansion of Medicaid eligibility was associated with a nearly 3-fold increase in the proportion of Medicaid-covered patients enrolled in cancer treatment trials.
Geriatric Screening and CARG Toxicity Assessment Tools Predict Adverse Outcomes
The G8 and CARG chemotherapy toxicity assessment tools were found to predict early hospitalization/ER visits and death in older patients with cancer.
Factors Associated With Non-Small Cell Lung Cancer Stage at Presentation
Researchers identified demographic and socioeconomic factors associated with differences in staging of non-small cell lung cancer at initial presentation.
High-Deductible Health Plans Linked to Delayed Diagnosis of Metastatic Cancer
Having a high-deductible health plan was associated with a nearly 5-month delay in the diagnosis of metastatic cancer.
Denosumab Improves Long-Term Outcomes in AI-Treated Breast Cancer
Patients who received denosumab had a significant improvement in disease-free survival and bone metastasis-free survival.
LDCT Screening Tied to Lower Incidence of Advanced Lung Cancer
The incidence of advanced lung cancer declined by 3 cases per 100,000 people per year in 2015-2018 relative to 2004-2014.
Camrelizumab, Apatinib, and Temozolomide Combo Produces Durable Responses in Acral Melanoma
The overall response rate was 66.7%, and the median duration of response was 17.5 months.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in ASCO 2022
Loading... 
Loading...